



**ANTIGENIC PEPTIDES OF EPSTEIN-BARR VIRUS
EARLY ANTIGEN IN NASOPHARYNGEAL
CARCINOMA**

By

Aini Juhaida Bt. Abu Samah

A dissertation submitted to the
Institute of Advanced Studies
University of Malaya
Kuala Lumpur

In partial fulfilment of the requirements for the
Degree of Master of Philosophy

Perpustakaan Universiti Malaya



A505607436

FEBRUARY 1997

ACKNOWLEDGEMENT

This thesis was made possible by a fellowship award from the University of Malaya which helped cover most of the costs and expenses incurred during my study.

I am especially grateful to Assoc. Prof. Sam Choon Kook and Assoc. Prof. Cheng Hwee Ming for their supervision, critical insights and invaluable suggestions during the research and writing of the thesis. I am also indebted to Prof. Prasad for providing NPC samples, Assoc. Prof. Chang K. W. and Assoc. Prof. Wong K.K. for non-NPC cancers samples, and Prof. Tan N. H. for the MacDNASIS program. I am also thankful to Dr. Sonneborn H.H. and Dr. Hinderer W. from Biotest, Germany for the recombinant proteins.

I am very much grateful to everyone in NPC lab - Chandrika, Padmini and Siew Choo for your companionship, support, comfort and encouragement to see me through many difficult moments. Mr. Chong for always being helpful and reliable, my coursemates for their caring and encouragement, Joyce and Annie for sharing their invaluable knowledge and warmth.

My utmost gratitude for my family; my parents for always trusting me with freedom of choice, my brother and wife, and Dik Non for being the best sister anyone can hope for. Thanks for sharing the tears and laughs with me.

Most importantly to You Allah, my utmost gratifications for the countless blessings.

ABSTRACT

This study used 3 recombinant EBV proteins namely p54 and p138 of the EA-D (early antigen - diffuse) and p23 of VCA (viral capsid antigen) as target antigens in ELISA system for NPC diagnosis. The IgA and IgG specific antibodies were analysed in ELISA and compared with EBV serology using indirect immunofluorescence technique (IIF). 85% of IgA-VCA IIF-positive NPC sera had IgA antibodies to p54, 76% had IgA-p138 and 79% had IgA-p23 antibodies. Interestingly, in another group of 46 IgA-VCA IIF- negative NPC sera, IgA-p54 was detected in 33%, IgA-p138 in 35% and IgA-p23 in 28% of the NPC samples. In contrast, only 4% of 163 NHS sera had IgA antibodies to p54, 19% had IgA-p138 and 15% had IgA-p23 antibodies. In control ENT disease serum samples, IgA-p54 was present in 14%, while both IgA-p138 and IgA-p23 showed 12% reactivities. With non-NPC cancer serum samples, IgA-p54 was present in 4%, IgA-p23 in 9% while none of the samples had antibody reactivities to IgA-p138.

Similar tests for serum IgG showed that in 146 NPC, all IgA-VCA IIF-positive sera contained IgG to p54. 73% of these sera were IgG-p138 positive while 88% were IgA-p23 positive. Again, of interest was the finding that in 61 IgA-VCA IIF-negative NPC sera, 74% had IgG-p54, 38% had IgG-p138 and 62% had IgG-p23 antibodies. In contrast, IgG-p54 was present only in 6%, IgG-p138 in 5% and IgG-p23 in 10% of 108 NHS samples. In control non-NPC cancer serum samples, IgG-p54 was detected in 23% and IgG-p23 in 41% of the samples. None of the EBV proteins reacted for serum IgG in control ENT disease samples. Preliminary data

indicate that IgA-p138 appears to have a prognostic potential. p54 was the most sensitive antigen for both IgA (85.3%) and IgG (92.3%) antibodies detection. In addition, the detection of IgG p54 in a substantial portion of IgA-VCA IIF-negative NPC sera is an important finding towards better monitoring of NPC.

In an effort to further simplify the EBV p54-ELISA, we analysed the complete p54 viral protein for linear epitopes that are recognized by IgG in NPC sera. A 10-mer peptide, RFYRSGIIAV, was identified as the immunodominant portion of the p54 EA protein. This peptide was able to identify 97% of NPC sera that were negative for IgA-VCA in IIF.

Hydropathy profiling using Hopp and Woods method (1983) was conducted to compare the predicted hydrophilic with antigenic regions as determined through the epitope PEPSCAN analyses. This was done for p54 as well as two other proteins in which PEPSCAN have been carried out previously, namely the nuclear antigen, EBNA1 and the replication activator, ZEBRA. There was very little correlation seen between the predicted epitope clusters and regions identified through PEPSCAN.

The present study has identified a 10-mer peptide, RFYRSGIIAV of EBV early antigen p54, as a potential valuable complementary test antigen for the diagnosis of NPC.

CONTENTS

	Page
ACKNOWLEDGEMENT	i
ABSTRACT	ii
CONTENTS	iii
LIST OF FIGURES	vii
LIST OF TABLES	x
 CHAPTER ONE	
1.0 NASOPHARYNGEAL CARCINOMA	1
1.1 CLINICAL SYMPTOMS OF NPC	2
1.2 CLASSIFICATIONS OF NPC	3
1.3 GEOGRAPHICAL AND RACE DISTRIBUTION OF NPC	6
1.4 ETIOLOGICAL FACTORS TO NPC	9
1.4.1 Genetic	9
1.4.2 Environmental Cofactors	13
1.5 EPSTEIN-BARR VIRUS	16
1.6 EPSTEIN-BARR VIRUS AND GENOME STRUCTURE	18
1.7 EBV TRANSMISSION AND STAGES OF INFECTION	22
1.7.1 Transmission	22
1.7.2 Infection	22
1.8 EPSTEIN-BARR VIRUS ANTIGENS	25

1.8.1	Epstein-Barr Virus Nuclear Antigens (EBNAs)	26
1.8.2	Viral Capsid Antigen (VCA)	30
1.8.3	BZLF1 Protein, ZEBRA	31
1.8.4	Early Antigen (EA)	33
1.9	EBV SEROLOGY	35
1.10	IMMUNOGENIC EPITOPE ANALYSIS BY PEPTIDE SYNTHESIS	38
1.11	ANTIGENIC EPITOPES AND PROTEIN SECONDARY STRUCTURE PREDICTIONS	44
 CHAPTER TWO		
2.0	MATERIALS AND METHODS	47
2.1	PROTEINS AND PEPTIDES	47
2.1.1	Recombinant proteins	47
2.1.2	Synthetic Peptides	48
2.2	SERUM SAMPLES	49
2.2.1	NPC Sera	49
2.2.2	Control Sera	49
2.2.3	Suspect NPC Sera	49
2.2.4	Immunoglobulin A Anti VCA (Iga-VCA) And IgG Anti EA (IgG-EA) Titers	50
2.3	PROTEIN HYDROPATHY PLOTS AND SECONDARY STRUCTURE PREDICTIONS	53
2.4	MULTIPIN PEPTIDE SYNTHESIS	54
2.4.1	Storage Of Multipin Peptide Synthesis Kit	54
2.4.2	Reaction Tray Numbering System And Pins Holder	54
2.4.3	Synthesis Procedures	57

2.5	ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)	62
2.5.1	Recombinant Proteins As Antigens In ELISA	62
2.5.2	PEPSCAN Using Enzyme-Linked Immunosorbent Assay	63

CHAPTER THREE

3.0	RESULTS	67
3.1	DETECTION OF IgA ANTIBODIES TO EBV RECOMBINANT PROTEINS	67
3.1.a.(i)	IgA-p54 (Early Antigen)	68
3.1.a.(ii)	IgA-p138 (Early Antigen)	68
3.1.a.(iii)	IgA-p23 (viral capsid antigen)	68
3.1.b.(i)	IgA Analysis In Suspect NPC Serum Samples	69
3.1.b.(ii)	IgA Analysis In Follow-up NPC Sera, Pre- And Post-therapy	70
3.2	DETECTION OF IgG ANTIBODIES TO EBV RECOMBINANT PROTEIN	80
3.2.a.(i)	IgG-p54 (Early Antigen)	80
3.2.a.(ii)	IgG-p138 (Early Antigen)	81
3.2.a.(iii)	IgG-p23 (Viral Capsid Antigen)	81
3.2.B.(i)	IgG Analysis In Suspect NPC Serum Samples	87
3.2.B.(ii)	IgG Analysis In Follow-up NPC Sera, Pre- And Post-therapy	87
3.3	DETECTION OF IgM ANTIBODIES TO EBV RECOMBINANT PROTEINS	88
3.4	MULTIPIN PEPTIDE SYNTHESIS	91
3.5	HYDROPATHY PLOTS AND SECONDARY STRUCTURE PREDICTIONS	109

CHAPTER FOUR

4.0	DISCUSSION	119
4.1	IgA AND IgG SERUM ANTIBODIES TO RECOMBINANT EAs (P54 AND P138) AND VCA (P23) PROTEINS IN ELISA	119
4.2	IgA AND IgG REACTIVITIES IN PRE- AND POST-TREATMENT NPC SERA	125
4.3	IgA AND IgG REACTIVITIES IN MULTIPIN PEPTIDES FROM PEPSCAN	127
4.4	ANTIGEN-ANTIBODY BINDING MECHANISMS	133
4.5	ASSOCIATION OF HYDROPATHY PROFILES, SECONDARY STRUCTURE AND PEPSCAN ANALYSIS	137
4.5.1	Hydropathy Profiles And Antigenicity	137
4.5.2	Recombinant EA p54	140
4.5.3	EBNA1	141
4.5.4	ZEBRA	142
4.5.5	Three- And 5-mer Peptides From Peptides 52, 53 and 54 of EA p54	143
	CONCLUSIONS	147
	REFERENCES	148
	APPENDICES	

LIST OF FIGURES

	Page
Figure 1.1: The Epstein-Barr virus	17
Figure 1.2: Linear EBV DNA and circular EBV episome showing the general organization of unique (U) and major internal repeats (IR) DNA domains (From Tosato, 1987; Fields, 1996)	19
Figure 2.1: Positive staining of IgA antibody to Epstein-Barr virus viral capsid antigen (VCA) detected by Indirect Immunofluorescence (IIF)	52
Figure 2.2: Negative staining of IgA antibody to Epstein-Barr virus viral capsid antigen (VCA) detected by Indirect Immunofluorescence (IIF)	52
Figure 2.3: Numbering system of tray in Mimotope as used by the software supplied with the synthesis kit. Wells are identified by a letter that represents the block, followed by the row number, which is then followed by the column number(s) in parenthesis. Assuming that this is block A, filled wells (dark) are identified as A1(1,2), A6(5,6) and A11(3,4); from top to bottom	56
Figure 3.1: IgA-p54 reactivities in NPC, NHS, ENT diseases and non-NPC cancers sera	73
Figure 3.2: IgA anti-p54 antibody binding and IgA-VCA IIF titers in NPC sera samples	74
Figure 3.3: IgA-p138 reactivities in NPC, NHS, ENT diseases and non-NPC cancers sera	75
Figure 3.4: IgA anti-p138 antibody binding and IgA-VCA IIF titers in NPC sera	76

Figure 3.5:	IgA-p23 reactivities in NPC, NHS, ENT diseases and non-NPC cancers sera	77
Figure 3.6:	IgA-p23 antibody binding and IgA-VCA levels in NPC sera	78
Figure 3.7:	IgG antibody to EBV recombinant EA p54 detected by ELISA	79
Figure 3.8:	IgG anti-p54 antibody binding by ELISA in NPC and control sera	83
Figure 3.9:	IgG anti-p138 antibody binding by ELISA in NPC and control sera	84
Figure 3.10:	IgG anti-p23 antibody binding by ELISA in NPC and control sera	85
Figure 3.11:	IgG antibody to EA p54 non-cleavable-pin-peptides 1-46 of recombinant EA p54	92
Figure 3.12:	Percent positivity of NPC sera (n=24) to 79, 10-residue peptide fragments of EA p54 for IgG antibodies	93
Figure 3.13:	IgG antibody reactivities in 5 NPC sera to 79, 10-residue peptides of EA p54, showing strength of absorbance to each peptide	94
Figure 3.14:	IgG anti-peptide 54 antibody binding and IgA-VCA IIF titers in NPC sera	102
Figure 3.15:	IgG anti-peptide 54 antibody and IgG-EA IIF titers in NPC sera	103
Figure 3.16:	IgG anti-peptide 54 antibodies and IgG anti-p54 recombinant EA ELISA in NPC sera (r=0.29)	104
Figure 3.17:	Hydropathy plot of recombinant p54 using method of Hopp & Woods (1983)	113

Figure 3.18:	Hydropathy plot of EBNA1 protein using method of Hopp & Woods (1983)	115
Figure 3.19:	Hydropathy plot of ZEBRA protein using method of Hopp & Woods (1983)	117
Figure 3.20:	Secondary structure of p54 recombinant EA protein as predicted by Chou & Fasman (1978)	118

LIST OF TABLES

	Page
Table 3.1: Percent positivity of IgA responses to the recombinant EAs and VCA proteins in various sera groups	71
Table 3.2: Presence of serum IgA anti-EBV proteins in pre- and post-treatment NPC cases	72
Table 3.3: IgG antibodies to p54, p138 and p23 EBV recombinant proteins in several sera groups	82
Table 3.4: Percent sensitivity and specificity of IgA and IgG to EBV recombinant proteins p54, p138 and p23	86
Table 3.5: Presence of serum IgG anti-EBV proteins in 21 pre- and post-treatment NPC cases	89
Table 3.6: Percent positivity of IgM antibody to recombinant proteins p54, p138 and p23 in NPC, NHS and sera of patients with clinical symptoms of NPC	90
Table 3.7: Percent positive IgG reactivities to EBV early antigen peptides 52, 53 and 54 in NPC and NHS (Initial results)	95
Table 3.8: Percent positive IgG reactivities to EBV early antigen peptides 52, 53 and 54 in 24 NPC sera	97
Table 3.9: Presence of IgA and IgG in paired serum-saliva to early antigen peptide 54	98
Table 3.10: Percent positive IgA reactivities to EBV early antigen peptides 52, 53 and 54 in NPC and NHS	99
Table 3.11: IgA and IgG reactivities in various sera groups against peptide 54	101

Table 3.12:	IgG reactivities in NPC and NHS sera against mimotopes	107
Table 3.13:	IgA reactivities in NPC and NHS sera against mimotopes	108
Table 3.14	Predicted antigenic regions of p54 early antigen and their corresponding peptide(s) reactivities in IgG from PEPSCAN studies	112
Table 3.15	Predicted antigenic regions of EBNA1 and their corresponding peptide(s) reactivities in IgA and IgG from PEPSCAN studies	114
Table 3.16	Predicted antigenic regions of ZEBRA and their corresponding peptide(s) reactivities in IgG from PEPSCAN studies	116
Table 4.1	Predicted hydrophilic regions (Hopp & Woods, 1981) of recombinant EA p54 and its corresponding predicted secondary structures (Chou & Fasman, 1978)	146